Suppr超能文献

生物制品病毒安全性问题处理方法的演变。

Evolution of approaches to viral safety issues for biological products.

作者信息

Lubiniecki Anthony S

机构信息

Portfolio Management, Pharmaceutical Development & Manufacturing Sciences, Johnson & Johnson Pharmaceutical Research & Development, Malvern, PA 19355, USA.

出版信息

PDA J Pharm Sci Technol. 2011 Nov-Dec;65(6):547-56. doi: 10.5731/pdajpst.2011.00818.

Abstract

CONFERENCE PROCEEDING Proceedings of the PDA/FDA Adventitious Viruses in Biologics: Detection and Mitigation Strategies Workshop in Bethesda, MD, USA; December 1-3, 2010 Guest Editors: Arifa Khan (Bethesda, MD), Patricia Hughes (Bethesda, MD) and Michael Wiebe (San Francisco, CA) Approaches to viral safety issues for biological products have evolved during the past 50+ years. The first cell culture products (viral vaccines) relied largely on the use of in vitro and in vivo virus screening assays that were based upon infectivity of adventitious viral agents. The use of Cohn fractionation and pasteurization by manufacturers of plasma derivatives introduced the concepts that purification and treatment with physical and chemical agents could greatly reduce the risk of viral contamination of human albumin and immunoglobulin products. But the limitations of such approaches became clear for thermolabile products that were removed early in fractionation such as antihemophilic factors, which transmitted hepatitis viruses and HIV-1 to some product recipients. These successes and limitations were taken into account by the early developers of recombinant DNA (rDNA)-derived cell culture products and by regulatory agencies, leading to the utilization of cloning technology to reduce/eliminate contamination due to human viruses and purification technologies to physically remove and inactivate adventitious and endogenous viruses, along with cell banking and cell bank characterization for adventitious and endogenous viruses, viral screening of biological raw materials, and testing of cell culture harvests, to ensure virus safety. Later development and incorporation of nanofiltration technology in the manufacturing process provided additional assurance of viral clearance for safety of biotechnology products. These measures have proven very effective at preventing iatrogenic infection of recipients of biotechnology products; however, viral contamination of production cell cultures has occasionally occurred. Screening tests for viral contamination in raw materials have not proven practical by themselves to prevent contamination of cell cultures, but they can be made more effective by coupling with treatment using physical or chemical agents to further reduce the hypothetical viral loads present in cell culture raw materials. Recent advances in polymerase chain reaction (PCR) technology have allowed preharvest testing for specific viral agents to reduce the risk of cell culture contamination by specific viruses in the harvest material. Examples of each of these stages in the evolution of virus detection methods are described and assessed in this paper.

摘要

会议论文集 《PDA/FDA生物制品中潜在病毒:检测与缓解策略研讨会论文集》,美国马里兰州贝塞斯达;2010年12月1日至3日 客座编辑:阿里法·汗(马里兰州贝塞斯达)、帕特里夏·休斯(马里兰州贝塞斯达)和迈克尔·维贝(加利福尼亚州旧金山) 在过去50多年里,生物制品病毒安全性问题的处理方法不断演变。首批细胞培养产品(病毒疫苗)很大程度上依赖基于潜在病毒因子感染性的体外和体内病毒筛选检测方法。血浆衍生物制造商采用的科恩分级分离法和巴氏消毒法引入了这样的概念,即通过物理和化学试剂进行纯化和处理可大幅降低人白蛋白和免疫球蛋白产品的病毒污染风险。但对于在分级分离早期就被去除的热不稳定产品,如抗血友病因子,这些方法的局限性变得明显,因为抗血友病因子曾将肝炎病毒和HIV-1传播给一些产品接受者。重组DNA(rDNA)衍生的细胞培养产品的早期开发者和监管机构考虑到了这些成功与局限,从而采用克隆技术减少/消除人源病毒污染,利用纯化技术物理去除并灭活潜在和内源性病毒,同时进行细胞库建立及细胞库中潜在和内源性病毒的鉴定、生物原材料的病毒筛选以及细胞培养收获物的检测,以确保病毒安全性。后来在生产过程中开发并纳入纳滤技术,为生物技术产品的安全性提供了额外的病毒清除保证。这些措施已被证明在预防生物技术产品接受者的医源性感染方面非常有效;然而,生产细胞培养物的病毒污染偶尔仍会发生。原材料中病毒污染的筛选检测本身并未被证明能切实预防细胞培养物的污染,但通过与物理或化学试剂处理相结合,可使其更有效,从而进一步降低细胞培养原材料中假设的病毒载量。聚合酶链反应(PCR)技术的最新进展使得在收获前对特定病毒因子进行检测成为可能,以降低收获材料中特定病毒导致细胞培养物污染的风险。本文描述并评估了病毒检测方法演变过程中每个阶段的实例。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验